Lassa hemorrhagic shock syndrome-on-a-chip.


Journal

Biotechnology and bioengineering
ISSN: 1097-0290
Titre abrégé: Biotechnol Bioeng
Pays: United States
ID NLM: 7502021

Informations de publication

Date de publication:
03 2021
Historique:
received: 07 10 2020
revised: 17 11 2020
accepted: 23 11 2020
pubmed: 27 11 2020
medline: 18 1 2022
entrez: 26 11 2020
Statut: ppublish

Résumé

Lack of experimental human models hinders research on Lassa hemorrhagic fever and the development of treatment strategies. Here, we report the first chip-based model for Lassa hemorrhagic syndrome. The chip features a microvessel interfacing collagen network as a simple mimic for extracellular matrix, allowing for quantitative and real-time vascular integrity assessment. Luminal infusion of Lassa virus-like particles led to a dramatic increase in vascular permeability in a viral load-dependent manner. Using this platform, we showed that Fibrin-derived peptide FX06 can be used to suppress the vascular integrity loss. This simple chip-based model proved promising in the assessment of disease severity and provides an easy-to-use platform for future investigation of Lassa pathogenesis and drug development in a human-like setting.

Identifiants

pubmed: 33241859
doi: 10.1002/bit.27636
pmc: PMC7983903
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1405-1410

Informations de copyright

© 2020 The Authors. Biotechnology and Bioengineering Published by Wiley Periodicals LLC.

Références

Nat Biomed Eng. 2017;1:
pubmed: 29038743
J Immunol. 2004 Mar 1;172(5):2731-8
pubmed: 14978070
Virol J. 2010 Oct 20;7:279
pubmed: 20961433
Lancet Infect Dis. 2018 Jun;18(6):684-695
pubmed: 29523497
Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8925-30
pubmed: 24889626
Nat Biotechnol. 2014 Aug;32(8):760-72
pubmed: 25093883
Nat Med. 2017 Oct;23(10):1146-1149
pubmed: 28869611
N Engl J Med. 2018 Nov 1;379(18):1745-1753
pubmed: 30332564
Nat Commun. 2016 May 10;7:11544
pubmed: 27161536
Lancet Infect Dis. 2019 Dec;19(12):1371-1378
pubmed: 31588039
NPJ Vaccines. 2018 Mar 20;3:11
pubmed: 29581897
Lab Chip. 2015 Jan 7;15(1):141-50
pubmed: 25317977
Clin Pharmacol Ther. 2018 Feb;103(2):332-340
pubmed: 28516446
Trends Microbiol. 2020 Nov;28(11):934-946
pubmed: 32674988
Int J Infect Dis. 2019 Oct;87:15-20
pubmed: 31357056
iScience. 2020 Jan 24;23(1):100765
pubmed: 31887664
Biotechnol Bioeng. 2021 Mar;118(3):1405-1410
pubmed: 33241859
Lab Chip. 2011 May 7;11(9):1596-602
pubmed: 21394334
Pathogens. 2020 Mar 06;9(3):
pubmed: 32155851
Nat Biomed Eng. 2020 Apr;4(4):394-406
pubmed: 31988457

Auteurs

Huaqi Tang (H)

Medical Systems Biophysics and Bioengineering, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.

Yasmine Abouleila (Y)

Medical Systems Biophysics and Bioengineering, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.

Alireza Mashaghi (A)

Medical Systems Biophysics and Bioengineering, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH